ArticleFrontiers in cardiovascular medicine2026
The C-reactive protein-triglyceride-glucose index predicts new-onset atrial fibrillation after ST-segment elevation myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C-Reactive Protein-Triglyceride Glucose Index and Mortality in Patients with Ventricular Septal Rupture After Acute Myocardial Infarction.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New-onset atrial fibrillation (NOAF) is a common complication following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), with a reported incidence of 6.3%-8.0%. It represents a significant risk factor for major adverse cardiovascular events (MACE) in this patient population. The C-reactive protein-triglyceride-glucose index (CTI), a composite biomarker reflecting both inflammatory (via high-sensitivity C-reactive protein, hs-CRP) and metabolic (via the triglyceride-glucose index, TyG index) pathways, has demonstrated prognostic potential for predicting MACE and mortality. Nevertheless, its specific utility in predicting NOAF among STEMI patients undergoing primary PCI has not been investigated. Methods: This retrospective study included 696 patients (mean age 63.9 ± 12.97 years) diagnosed with acute ST-elevation myocardial infarction. Clinical data were collected to calculate the TyG index = ln[TG(mg/dL) × FBG(mg/dL)/2] and the CTI = 0.412 × [CRP(mg/L)] + ln[(TG(mg/dL) × FBG(mg/dL))/2]. NOAF was defined as atrial fibrillation occurring for the first time within 30 days after primary PCI. Multivariate logistic regression was used to assess the association between CTI and NOAF. Receiver operating characteristic (ROC) analysis was used to evaluate the predictive value of the CTI, the TyG index and high-sensitivity hs-CRP, with area under the curve (AUC) differences being determined via DeLong's test. Results: Of 696 initially screened participants, 62 (8.9%) developed NOAF. Multivariate analysis (stepwise forward method) confirmed CTI, Age, LVEF, and IRA-RCA as independent predictors of post-primary PCI NOAF. In ROC analysis, the CTI demonstrated superior discriminative power for NOAF with an AUC of 0.741, compared to the TyG index (AUC = 0.686) and hs-CRP (AUC = 0.664), and the Delong test confirmed that these differences were statistically significant. Combining CTI with conventional clinical indicators further improved NOAF risk stratification (AUC = 0.795). Conclusions: CTI is an independent risk factor for post-primary PCI NOAF in STEMI patients. It exhibits superior predictive value for NOAF compared to hs-CRP or TyG index alone, making it a clinically useful tool for risk stratification in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.